Table 5.
Opportunistic Infection Treatment for 286 Patients Followed up to 180 Days
| 114 TB | 14 NTM | 99 Histoplasmosis | 59 Cryptococcosis | |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | |
| AmB | — | — | 21 (21.2) | 1 (1.7) |
| AmB followed by FZ | — | — | 4 (4.0) | 23 (39.0) |
| AmB followed by ITZ | — | — | 31 (31.3) | — |
| FZ | — | — | 3 (3.0) | 22 (37.3) |
| ITZ | — | — | 21 (21.2) | — |
| Antibiotics | — | 5 (35.7) | — | — |
| Anti-TB drugs | 98 (86) | 5 (35.7) | — | — |
| No treatment or unknowna | 16 (14) | 4 (28.6) | 19 (19.2) | 13 (22.0) |
Abbreviations: AmB, conventional amphotericin B; FZ, fluconazole; ITZ, itraconazole; NTM, nontuberculous mycobacteria; TB, tuberculosis.
aThirteen patients dead immediately after admission; 19 were lost to follow-up, and there is no evidence that they received treatment; 15 refused the treatment (death was confirmed using the National Registry), and 5 did not receive treatment for other reasons.